Predictors of fatal outcomes among hospitalized COVID-19 patients with pre-existing hypertension in China

被引:7
作者
Wang, Tao [1 ,2 ]
Tang, Ruidi [1 ,2 ]
Ruan, Honglian [3 ]
Chen, Ruchong [1 ]
Zhang, Zili [1 ,2 ]
Sang, Ling [1 ]
Su, Xi [4 ]
Yi, Shuting [4 ]
Ni, Zhengyi [5 ]
Hu, Yu [6 ]
Liu, Lei [7 ,8 ]
Shan, Hong [9 ]
Lei, Chunliang [10 ]
Peng, Yixiang [11 ]
Liu, Chunli [1 ]
Li, Jing [1 ]
Hong, Cheng [1 ]
Zhang, Nuofu [1 ]
Zhong, Nanshan [1 ]
Li, Shiyue [1 ]
机构
[1] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis,Guangzhou Inst Resp Hlth, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China
[2] Guangzhou Med Univ, Guangdong Key Lab Vasc Dis, Guangzhou, Peoples R China
[3] Guangzhou Med Univ, Sch Publ Hlth, Guangzhou, Peoples R China
[4] Guangzhou Med Univ, Guangzhou, Peoples R China
[5] Wuhan Jin Yin Tan Hosp, Wuhan, Peoples R China
[6] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[7] Shenzhen Third Peoples Hosp, Shenzhen, Peoples R China
[8] Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, Affiliated Hosp 2, Shenzhen, Peoples R China
[9] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China
[10] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China
[11] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Wuhan, Peoples R China
基金
美国国家科学基金会;
关键词
blood pressure control; cardiac injury; COVID-19; hypertension; renin-angiotensin-aldosterone system suppressors;
D O I
10.1111/crj.13382
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Coronavirus disease 2019 (COVID-19) is an emerging, rapidly evolving pandemic, hypertension is one of the most common co-existing chronic conditions and a risk factor for mortality. Nearly one-third of the adult population is hypertensive worldwide, it is urgent to identify the factors that determine the clinical course and outcomes of COVID-19 patients with hypertension. Methods and results 148 COVID-19 patients with pre-existing hypertension with clarified outcomes (discharge or deceased) from a national cohort in China were included in this study, of whom 103 were discharged and 45 died in hospital. Multivariate regression showed higher odds of in-hospital death associated with high-sensitivity cardiac troponin (hs-cTn) > 28 pg/ml (hazard ratio [HR]: 3.27, 95% confidence interval [CI]: 1.55-6.91) and interleukin-6 (IL-6) > 7 pg/ml (HR: 3.63, 95% CI:1.54-8.55) at admission. Patients with uncontrolled blood pressure (BP) (n = 52) which were defined as systolic BP >= 140 mm Hg or diastolic BP >= 90 mm Hg for more than once (>= 2 times) during hospitalization, were more likely to have ICU admission (p = 0.037), invasive mechanical ventilation (p = 0.028), and renal injury (p = 0.005). A stricter BP control with the threshold of 130/80 mm Hg was associated with lower mortality. Treatment with renin-angiotensin-aldosterone system (RAAS) suppressors, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), and spironolactone, was associated with a lower rate of ICU admission compared to other types of anti-hypertensive medications (8 (22.9%) vs. 25 (43.1%), p = 0.048). Conclusion Among COVID-19 patients with pre-existing hypertension, elevated hs-cTn and IL-6 could help clinicians to identify patients with fatal outcomes at an early stage, blood pressure control is associated with better clinical outcomes, and RAAS suppressors do not increase mortality and may decrease the need for ICU admission.
引用
收藏
页码:915 / 924
页数:10
相关论文
共 22 条
  • [11] Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
    Richardson, Safiya
    Hirsch, Jamie S.
    Narasimhan, Mangala
    Crawford, James M.
    McGinn, Thomas
    Davidson, Karina W.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (20): : 2052 - 2059
  • [12] The CC chemokine CCL20 and its receptor CCR6
    Schutyser, E
    Struyf, S
    Van Damme, J
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (05) : 409 - 426
  • [13] Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
    Shi, Shaobo
    Qin, Mu
    Shen, Bo
    Cai, Yuli
    Liu, Tao
    Yang, Fan
    Gong, Wei
    Liu, Xu
    Liang, Jinjun
    Zhao, Qinyan
    Huang, He
    Yang, Bo
    Huang, Congxin
    [J]. JAMA CARDIOLOGY, 2020, 5 (07) : 802 - 810
  • [14] Response to COVID-19 in Taiwan Big Data Analytics, New Technology, and Proactive Testing
    Wang, C. Jason
    Ng, Chun Y.
    Brook, Robert H.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (14): : 1341 - 1342
  • [15] Status of Hypertension in China Results From the China Hypertension Survey, 2012-2015
    Wang, Zengwu
    Chen, Zuo
    Zhang, Linfeng
    Wang, Xin
    Hao, Guang
    Zhang, Zugui
    Shao, Lan
    Tian, Ye
    Dong, Ying
    Zheng, Congyi
    Wang, Jiali
    Zhu, Manlu
    Weintraub, William S.
    Gao, Runlin
    [J]. CIRCULATION, 2018, 137 (22) : 2344 - 2356
  • [16] Clinical course and mortality risk of severe COVID-19
    Weiss, Paul
    Murdoch, David R.
    [J]. LANCET, 2020, 395 (10229) : 1014 - 1015
  • [17] 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines (vol 71, pg e127, 2018)
    Whelton, P. K.
    Carey, R. M.
    Aronow, W. S.
    Casey, D. E., Jr.
    Collins, K. J.
    Himmelfarb, Dennison C.
    DePalma, S. M.
    Gidding, S.
    Jamerson, K. A.
    Jones, D. W.
    MacLaughlin, E. J.
    Muntner, P.
    Ovbiagele, B.
    Smith, S. C., Jr.
    Spencer, C. C.
    Stafford, R. S.
    Taler, S. J.
    Thomas, R. J.
    Williams, K. A., Sr.
    Williamson, J. D.
    Wright, J. T., Jr.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (19) : 2275 - 2279
  • [18] 2018 ESC/ESH Guidelines for the management of arterial hypertension
    Williams, Bryan
    Mancia, Giuseppe
    Spiering, Wilko
    Rosei, Enrico Agabiti
    Azizi, Michel
    Burnier, Michel
    Clement, Denis L.
    Coca, Antonio
    de Simone, Giovanni
    Dominiczak, Anna
    Kahan, Thomas
    Mahfoud, Felix
    Redon, Josep
    Ruilope, Luis
    Zanchetti, Alberto
    Kerins, Mary
    Kjeldsen, Sverre E.
    Kreutz, Reinhold
    Laurent, Stephane
    Lip, Gregory Y. H.
    McManus, Richard
    Narkiewicz, Krzysztof
    Ruschitzka, Frank
    Schmieder, Roland E.
    Shlyakhto, Evgeny
    Tsioufis, Costas
    Aboyans, Victor
    Desormais, Ileana
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (33) : 3021 - +
  • [19] Effective treatment of severe COVID-19 patients with tocilizumab
    Xu, Xiaoling
    Han, Mingfeng
    Li, Tiantian
    Sun, Wei
    Wang, Dongsheng
    Fu, Binqing
    Zhou, Yonggang
    Zheng, Xiaohu
    Yang, Yun
    Li, Xiuyong
    Zhang, Xiaohua
    Pan, Aijun
    Wei, Haiming
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (20) : 10970 - 10975
  • [20] Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension A Single-Center Retrospective Study
    Yang, Guang
    Tan, Zihu
    Zhou, Ling
    Yang, Min
    Peng, Lang
    Liu, Jinjin
    Cai, Jingling
    Yang, Ru
    Han, Junyan
    Huang, Yafei
    He, Shaobin
    [J]. HYPERTENSION, 2020, 76 (01) : 51 - 58